JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
JAK2 mutation has not been described in patients with chronic lymphocytic leukemia (CLL). We found JAK2 mutation in a patient with CLL and coexisting myeloproliferative neoplasm (MPN). In this patient, we demonstrated the presence of the JAK2 mutation in CD34(+) progenitor cells, myeloid lineage cells, megakaryocytes, B lymphocytes but not in T lymphocytes. This case represents the first case report of JAK2 mutation in CLL and may also suggest that, JAK2 mutation most likely represents a secondary event from primary gene mutations involving the primitive stem cells which give rise to MPN and CLL. Furthermore, in this case, we believe that we are the first to demonstrate that JAK2 mutation in myeloid and B lymphoid cells but not T lymphocytes in a case of coexisting CLL and MPN.
Kodali
Srinivas
S
Brookdale University Hospital and Medical Center, Brooklyn, NY 11212, USA.
Chen
Chi
C
Rathnasabapathy
Chenthilmurugan
C
Wang
Jen Chin
JC
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053614:Janus Kinase 2 / Q000235:genetics*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications*; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000150:complications / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D053614:Janus Kinase 2